Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P376: Improving stress and fatigue in a real-world setting among patients with Inflammatory Bowel Disease through a digital platformECCO'21 Virtual
Year: 2021
Authors: Oddsson, S.(1);Gunnarsdottir, T.(1);Johannsdottir, L.(2);Amundadottir, M.(3);Frimannsdottir, A.(3);Ylanne, K.(4);Molander, P.(5);Islind, A.(2);Oskarsdottir, M.(2);Thorgeirsson, T.(1);
(1)Sidekick Health, Medical and Research Department, Kopavogur, Iceland;(2)Reykjavik University, Department of Computer Science, Reykjavik, Iceland;(3)Sidekick Health, Data Science Department, Kopavogur, Iceland;(4)Sidekick Health, Customer Success Department, Kopavogur, Iceland;(5)Helsinki University Hospital- Helsinki University, Abdominal Center- Gastroenterology, Helsinki, Finland
P377: Inadequate response with advanced therapies in real-world patients with Ulcerative Colitis – Results of a German claims database studyECCO'21 Virtual
Year: 2021
Authors: Bokemeyer, B.(1);Picker, N.(2);Wilke, T.(3);Rosin, L.(4);Patel, H.(5);
(1)Interdisziplinäres Crohn Colitis Center Minden und Medizinische Klinik I- Universitätsklinik Schleswig-Holstein- Campus Kiel, Gastroenterologische Praxis Minden, Minden, Germany;(2)Ingress Health, HWM GmbH, Wismar, Germany;(3)IPAM, e.V., Wismar, Germany;(4)Galapagos, Biopharma Deutschland GmbH, München, Germany;(5)Galapagos, Nv, Mechelen, Belgium
P378: Oxidative status and antioxidant capacity in children and adults with IBD: preliminary results of the OxIBDiet trialECCO'21 Virtual
Year: 2021
Authors: Gatti, S.(1);Cianfruglia, L.(2);Galeazzi, T.(1);Palpacelli, A.(1);Quattrini, S.(1);Quatraccioni, C.(3);Catassi, G.(1);Monachesi, C.(1);Di Sario, A.(3);Armeni, T.(2);Catassi, C.(1);
(1)Polytechnic University of Marche, Department of Pediatrics, Ancona, Italy;(2)Polytechnic University of Marche, Department of Clinical Sciences, Ancona, Italy;(3)Polytechnic University of Marche, Department of Gastroenterology, Ancona, Italy
P379: Variations in disease monitoring between Inflammatory Bowel Disease patients on intravenous and subcutaneous biologic agents.ECCO'21 Virtual
Year: 2021
Authors: Hilley, P.(1);Li Wai Suen, C.(1,2);Srinivasan, A.(1,2);Choy, M.C.(1,2);De Cruz, P.(1,2);
(1)AUSTIN HEALTH, Gastroenterology, Melbourne, Australia;(2)University of Melbourne, Department of Medicine- Austin Academic centre, melbourne, Australia
P380: Comparison of mucosal healing through segments of ileocolonic Crohn’s disease treated with biologicsECCO'21 Virtual
Year: 2021
Authors: Temido, M.J.(1);Portela, F.(1);Lopes, S.(1);Mendes, S.(1);Ferreira, M.(1);Ferreira, M.(1);Figueiredo, P.(1);
(1)Centro Hospitalar e Universitário de Coimbra, Gastroenterology, Coimbra, Portugal
P381: Fatigue is an independent disease manifestation largely independent of chronicity, comorbidity and disease activity in patients with Inflammatory Bowel DiseaseECCO'21 Virtual
Year: 2021
Authors: Risager Christensen, K.(1);Steenholdt, C.(1);Buhl, S.(1);Skougaard, M.(2);Brynskov, J.(1);Ainsworth, M.A.(3);Schjødt Jørgensen, T.(2);Kristensen, L.E.(2);
(1)Gentofte and Herlev Hospital, Gastroenterology, Herlev, Denmark;(2)The Parker Institute- Copenhagen University Hospital, Rheumatology, Copenhagen, Denmark;(3)Odense University Hospital, Gastroenterology, Odense, Denmark
P382: High anti-tumor necrosis factor alpha treatment trough concentrations are not associated with higher rate of adverse events in pediatric patients with inflammatory bowel diseaseECCO'21 Virtual
Year: 2021
Authors: Zvuloni, M.(1);Matar, M.(2);Levi, R.(3);Shamir, R.(1,2);Assa, A.(2,4);
(1)The Sackler Faculty of Medicine- Tel Aviv University- Israel, Medicine department, Tel Aviv, Israel;(2)Schneider Children's Hospital, The institute of Gastroenterology- Nutrition and Liver diseases, Petach-Tikva, Israel;(3)Schneider Children's Hospital, Pediatric department A, Petach-Tikva, Israel;(4)The Ben-Gurion University of the Negev-- Israel, Medicine department, Beer Sheva, Israel
P383: Relationship between histo-endoscopic mucosal healing and baseline characteristics in patients with moderately to severely active Ulcerative Colitis receiving filgotinib in the phase 2b/3 SELECTION studyECCO'21 Virtual
Year: 2021
Authors: Peyrin-Biroulet , L.(1);Loftus Jr , E.V.(2);Hibi , T.(3);Birchwood , C.(4);Yun , C.(4);Zhao , S.(4);Liu , X.(4);Rogler , G.(5);Danese , S.(6);Colombel , J.F.(7);Feagan , B.(8);
(1)University Hospital of Nancy-University of Lorraine, Department of Gastroenterology and Inserm U954, Vandoeuvre-Lès-Nancy, France;(2)Mayo Clinic, Department of Internal Medicine-Department of Gastroenterology and Hepatology, Rochester, United States;(3)Kitasato Institute Hospital-Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(4)Gilead Sciences, Inc., Foster City, United States;(5)University Hospital of Zurich-University of Zurich, Clinic for Gastroenterology and Hepatology, Zurich, Switzerland;(6)Humanitas Clinical and Research Center-IRCCS and Humanitas University, Department of Gastroenterology, Milan, Italy;(7)Icahn School of Medicine at Mount Sinai, The Dr. Henry D. Janowitz Division of Gastroenterology-Department of Medicine, New York City, United States;(8)Western University, Department of Medicine-Division of Gastroenterology, London, Canada
P384: Therapeutic drug monitoring: performance of the first lateral flow-based Point of Care test for the quantification of infliximab in a finger prickECCO'21 Virtual
Year: 2021
Authors: Ametzazurra, A.(1);Pascual, J.(1);Del Rio, L.(1);Maguregui, A.(1);Nagore, D.(1);Ruiz-Argüello, M.B.(1);
(1)Progenika Biopharma - Grifols, Research & Development, Derio, Spain
P385: Results of a teleconsultation campaign for Inflammatory Bowel Disease (IBD) patients to check their treatment adherence and assess their level of anxiety during the first COVID-19 lockdownECCO'21 Virtual
Year: 2021
Authors: Paupard, T.(1);richez, C.(2);verlynde, J.(1);zaharia, O.(1);quartier, G.(1);hudziak, H.(1);delhoustal, L.(1);
(1)Centre Hospitalier, Service d'Hépato-Gastroentérologie, Dunkerque, France;(2)Centre Hospitalier, Service d'Addictologie, Dunkerque, France
P386: Two year follow up of children with Inflammatory Bowel Disease (IBD) treated with vedolizumab and ustekinumabECCO'21 Virtual
Year: 2021
Authors: Mardare, R.(1);Burgess, N.(1);Studart, D.(1);Deb, P.(1);Gasparetto, M.(1);Croft, N.(1);Naik, S.(1);Kadir, A.(1);
(1)Royal London Hospital, Paediatric Gastroenterology, London, United Kingdom
P387: Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemicECCO'21 Virtual
Year: 2021
Authors: Lin, S.(1,2);Bewshea, C.(2);Chanchlani, N.(2);Chee, D.(1,2);Pollok, R.C.(3,4);Kennedy, N.A.(1,2);Ahmad, T.(1,2);Goodhand, J.R.(1,2);
(1)Royal Devon and Exeter NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom;(2)University of Exeter, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, United Kingdom;(3)St George's University Hospital NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(4)St George's- University of London, Institute for Infection & Immunity, London, United Kingdom
P388: Agreement between locally and centrally reviewed Mayo endoscopic subscores in the UNIFI study of ustekinumab in patients with Ulcerative ColitisECCO'21 Virtual
Year: 2021
Authors: Mishkin, D.(1);Marano, C.(2);Simi, A.(2);Lynch, J.(2);Noonan, L.(2);Zhang, H.(2);Sands, B.E.(3);Reinisch, W.(4);
(1)Atrius Health, Gastroenterology, Boston, United States;(2)Janssen Research & Development- LLC, Immunology, Spring House, United States;(3)Mount Sinai School of Medicine, Henry D. Janowitz Division of Gastroenterology, New York, United States;(4)Medical University of Vienna, Gastroenterology, Vienna, Austria; UNIFI
P389: Efficacy and safety of ustekinumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor: real clinical practiceECCO'21 Virtual
Year: 2021
Authors: Saiz Chumillas, R.M.(1);Alba Hernández, L.(1);Chivato Martín-Falquina, I.(1);Badia Aranda, E.(1);Arias García, M.L.(1);Sicilia Aladrén, B.(1);
(1)University Hospital of Burgos, IBD Deparment, Burgos, Spain
P390: Diverting Loop Ileostomy in Medically Refractory Crohn's ColitisECCO'21 Virtual
Year: 2021
Authors: Patel, P.(1);Wu, L.(2);
(1)Mid Central District Health Board, General Surgery, Palmerston North, New Zealand;(2)Waikato District Health Board, General Surgery, Waikato, New Zealand
P391: Antibiotics in pediatric Inflammatory Bowel Diseases: a systematic reviewECCO'21 Virtual
Year: 2021
Authors: Verburgt, C.(1,2);Heutink, W.P.(3);Kuilboer, L.I.M.(1);Dickmann, J.D.(1);van Etten-Jamaludin, F.S.(4);Benninga, M.A.(1);de Jonge, W.J.(2,5);Van Limbergen, J.E.(1,2,6);Tabbers, M.M.(1);
(1)Emma Children’s Hospital- Amsterdam University Medical Centers, Department of Pediatric Gastroenterology and Nutrition, Amsterdam, The Netherlands;(2)Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands;(3)Wilhelmina Children’s Hospital- University Medical Center Utrecht, Department of Pediatrics, Utrecht, The Netherlands;(4)Amsterdam University Medical Centers, Research support- Medical library, Amsterdam, The Netherlands;(5)University of Bonn, Department of Surgery, Bonn, Germany;(6)Dalhousie University, Department of Pediatrics, Halifax, Canada
P392: A mobile application to monitor Inflammatory Bowel Disease patients during intravenous biologic treatment: Results of a feasibility studyECCO'21 Virtual
Year: 2021
Authors: Van Erp, L.W.(1);Groenen, M.J.M.(1);Heida, W.(1);Wisse, J.(1);Roosenboom, B.(1);Wahab, P.J.(1);
(1)Rijnstate Hospital, Crohn & Colitis Centre- Department of Gastroenterology and Hepatology, Arnhem, The Netherlands
P393: Treatment patterns of patients with perianal fistulizing Crohn’s disease from a US administrative claims databaseECCO'21 Virtual
Year: 2021
Authors: Cazzetta, S.(1);Chen, G.(2);Pedarla, V.(3);Null, K.(4);Rana Khan, Q.(1);Schwartz, D.(5);
(1)Takeda Pharmaceuticals USA- Inc., Medical Affairs, Lexington, United States;(2)At the time of the study Takeda Pharmaceuticals USA- Inc., Clinical Pharmacology, Lexington, United States;(3)Statinmed Research, Research, Plano, United States;(4)Takeda Pharmaceuticals USA- Inc., Outcomes Research & Data Science, Lexington, United States;(5)Vanderbilt University Medical Center, Inflammatory Bowel Disease Center, Nashville, United States
P394: Serological biomarkers of type III and IV collagen remodeling predict and monitor infliximab treatment response in patients with Inflammatory Bowel DiseaseECCO'21 Virtual
Year: 2021
Authors: Sorokina Alexdóttir, M.(1);Bourgonje, A.R.(2);Asser Karsdal, M.(1);Bay-Jensen, A.C.(1);Faber, K.N.(2);Loveikyte, R.(2);van Dullemen, H.M.(2);Visschedijk, M.C.(2);Festen, E.A.M.(2);K. Weersma, R.(2);Dijkstra, G.(2);Mortensen, J.H.(1);
(1)Nordic Bioscience, Immunoscience, Herlev, Denmark;(2)University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands
P395: Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn’s diseaseECCO'21 Virtual
Year: 2021
Authors: Pai, R.(1);De Hertogh, G.(2);Reinisch, W.(3);Harpaz, N.(4);Feagan, B.(5);Agada, N.(6);Pollack, P.(6);Chan, L.S.(6);Protic, M.(6);Magro, F.(7);
(1)The Mayo Clinic, Laboratory Medicine/Pathology, Scottsdale, United States;(2)University Hospitals Leuven, Pathology, Leuven, Belgium;(3)Medical University Vienna, Internal Medicine, Vienna, Austria;(4)Icahn School of Medicine at Mount Sinai, Pathology and Medicine, New York, United States;(5)Robarts Clinical Trials Inc, Medicine, London, Canada;(6)Eli Lilly and Company, Biomedicines, Indianapolis, United States;(7)University of Porto, Biomedicine, Porto, Portugal